A study of a weight-adjusted aprotinin dosing schedule during cardiac surgery.
Aprotinin is effective during cardiac surgery for reducing blood loss and transfusion requirements, but it is expensive. Aprotinin is usually administered to adults according to a fixed protocol regardless of the patient's weight. We previously developed a weight-based dosing protocol for aprotinin. The purpose of this prospective observational study was to determine aprotinin levels in four patient groups (n = 10 each) using the new weight-based aprotinin dosing schedule that should achieve concentrations over 100, 150, 200, and 250 kallikrein inhibitory units/mL compared with full-dose aprotinin regimen (n = 10) by a simple functional aprotinin assay. There was no difference in patient demographic or surgical variables among groups. There was less within patient variation in plasma aprotinin concentrations over time in the new weight-based aprotinin dosing schedule groups compared with the full-dose aprotinin regimen group (P < 0.02 for all comparisons). The mean plasma aprotinin concentration achieved with the new weight-based aprotinin dosing schedule was similar to the desired concentrations, but we were unable to reduce between-patient variability in aprotinin concentrations.


CONCLUSIONS
The current dosing schedule for aprotinin results in a large variation in aprotinin plasma concentrations between patients and a large variation within each patient over time. A new weight-based dosing schedule reduced variation of aprotinin concentration over time, but was unable to reduce between-patient variability in aprotinin concentration.
Nuttall
Gregory A
GA
Department of Anesthesiology, Mayo Graduate School of Medicine, Rochester, Minnesota 55905, USA. nutall.gregory@mayo.edu
Fass
David N
DN
Oyen
Lance J
LJ
Oliver
William C
WC
Ereth
Mark H
MH
D000368:Aged; D007611:Aprotinin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D016063:Blood Loss, Surgical; D001803:Blood Transfusion; D001835:Body Weight; D006348:Cardiac Surgical Procedures; D002315:Cardiopulmonary Bypass; D005260:Female; D006490:Hemostatics / Q000008:administration & dosage* / Q000493:pharmacokinetics; D006801:Humans; D008297:Male; D011446:Prospective Studies
D006490:Hemostatics; D007611:Aprotinin